Test directory: 14-3-3 protein

Ordering Code 7882
Test Name 14-3-3 protein
Alias 14-3-3
T-tau protein
RT-QuIC
prion
CJD
Creutzfeldt-Jakob
Preferred Specimen Cerebral Spinal Fluid
Preferred Container Cerebral Spinal Fluid Kit Tubes
Optimum Volume 5 mL
Collection Instructions Discard first 2 mL of CSF from the tap. Collect 2-5 mL clear +colorless CSF and freeze immediately at -20 to -80 degrees C
Case Western form must be completed by the client: https://case.edu/medicine/pathology/sites/case.edu
pathology/files/2023-10/Test%20Request%20Form.pdf
Transport Requirements Oahu: Frozen
Airline: Frozen
Specimen Stability Ambient: 24 Hours
Refrigerated: 14 Days
Frozen: Indefinite
Rejection Criteria Bloody CSF cannot be accurately tested
Avail. Stat NO
Analytic Time 10 Days
Methodology Immunoassay;
Real-time quaking-induced conversion (RT-QuIC)
Reference Lab  Nat'l Prion Disease Surveillance Ctr

Reference range(s)

The reference ranges listed below are valid on this date of May 25, 2025.
Component Age Male Norm Male Critical Low Male Critical High Female Norm Female Critical High Female Critical Low Units Add'l info
RT-QuIC (CSF) ALL NEGATIVE NEGATIVE
RT-QuIC identifies... RT-QuIC identifies the disease-causing agent
Note1
T-Tau protein (CSF) ALL 0-1149 0-1149 pg/mL
14-3-3 GAMMA (CSF) ALL 173-1999 173-1999 AU/mL
T-tau protein and 14... T-tau protein and 14-3-3 GAMMA are indirect markers of neurodegenerative disease.
Note2
Likelihood of prion disease ALL %

This test was...
This test was developed and its performance characteristics determined by the National Prion
Disease Pathology and Surveillance Center
Clinical Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration
The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. These assays should be used in conjunction with other clinical, pathological and laboratory findings
This laboratory is certified under the Clinical
Laboratory Improvement Amendments (CLIA) as qualified to perform clinical laboratory testing

See report.
Note3

Note1:

RT-QuIC identifies the disease-causing agent.

Note2:

T-tau protein and 14-3-3 GAMMA are indirect markers of neurodegenerative disease..

Note3:


This test was developed and its performance characteristics determined by the National Prion
Disease Pathology and Surveillance Center
Clinical Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration
The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. These assays should be used in conjunction with other clinical, pathological and laboratory findings
This laboratory is certified under the Clinical
Laboratory Improvement Amendments (CLIA) as qualified to perform clinical laboratory testing

See report..